Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.39 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.39 |
| ▸ | MTOR | P42345 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GRM8 | O00222 | 1/20 | 0.39 |
| ▸ | GRM6 | O15303 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.39 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30770084 | 1.00 | APLNR (0.43) | APLNRCYP2C19LMNAGRM2GRM3 | |
| SCHEMBL31250265 | 0.83 | GRM2 (0.33) | APLNRCYP2C19LMNAGRM2GRM3 | |
| SCHEMBL17540952 | 0.80 | ALDH1A1 (0.36) | TP53SMN1; SMN2ALDH1A1POLB | |
| SCHEMBL21013832 | 0.78 | ALOX15 (0.32) | LMNAALOX15ALDH1A1 | |
| SCHEMBL19550863 | 0.77 | APLNR (0.52) | APLNRCYP2C19LMNAGRM2GRM3 | |
| SCHEMBL21434917 | 0.77 | APLNR (0.52) | APLNRCYP2C19LMNAGRM2GRM3 | |
| SCHEMBL21434918 | 0.77 | APLNR (0.52) | APLNRCYP2C19LMNAGRM2GRM3 | |
| SCHEMBL873124 | 0.77 | — | — | |
| SCHEMBL5532753 | 0.75 | APLNR (0.48) | APLNRCYP2C19LMNAGRM2GRM3 | |
| SCHEMBL1813813 | 0.74 | TSHR (0.36) | APLNRCYP2C19LMNAGRM2GRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727939-A1 | 5-(CINNOLIN-6-YL)THIAZOLE COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2026-04-22 | — | — | EP | disclosed |
| WO-2024259116-A1 | 5-(CINNOLIN-6-YL)THIAZOLE COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2024-12-19 | — | — | WO | disclosed |
| US-20230391760-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. | 2023-12-07 | — | — | US | disclosed |
| EP-4229050-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022078407-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3185865-B1 | TETRAHYDRONAPTHTYRIDINE DERIVATIVES AS MGLUR2 NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE. | MERCK SHARP & DOHME (US) | 2020-07-15 | — | — | EP | disclosed |
| US-10072003-B2 | Tetrahydronaphthyridine derivatives as mGluR2-negative allosteric modulators, compositions, and their use | MERCK SHARP & DOHME CORP. | 2018-09-11 | — | — | US | disclosed |
| US-20170305902-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2017-10-26 | — | — | US | disclosed |
| EP-3185865-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | Merck Sharp & Dohme Corp. (US) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016032921-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2016-03-03 | — | — | WO | disclosed |
| WO-2016029454-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072003-B2 | Tetrahydronaphthyridine derivatives as mGluR2-negative allosteric modulators, compositions, and their use | GRIN2A, GRIN2C, GRIN2B | APLNR 445/4885CYP2C19 2567/4885LMNA 3546/4885 |
| US-20170305902-A1 | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | GRIN2A, GRIN2C, GRIN2B | APLNR 445/4885CYP2C19 2567/4885LMNA 3546/4885 |
| US-20230391760-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | APLNR 799/4885CYP2C19 734/4885LMNA 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.